RESUMO
Chanarin-Dorfman syndrome (CDS) is a rare, autosomal recessive disorder of impaired triacylglycerol catabolism leading to cytoplasmic deposition of triglycerides in various cell types. We describe the case of an 8-month-old boy with cataracts, strabismus, motor delays, and an ichthyosiform rash since birth. Genetic testing revealed a pathogenic variant of the ABHD5 gene, suggestive of CDS, and further workup demonstrated hepatic steatosis and myopathy. His ichthyosis improved with initiation of a diet low in very long-chain fatty acids and medium-chain fatty acid supplementation.
Assuntos
Catarata , Eritrodermia Ictiosiforme Congênita , Ictiose Lamelar , Ictiose , Erros Inatos do Metabolismo Lipídico , Doenças Musculares , Masculino , Humanos , Lactente , Eritrodermia Ictiosiforme Congênita/diagnóstico , Eritrodermia Ictiosiforme Congênita/genética , Ictiose Lamelar/diagnóstico , Ictiose Lamelar/genética , Ictiose/diagnóstico , Ictiose/genética , Doenças Musculares/diagnóstico , Doenças Musculares/genética , Doenças Musculares/patologia , Erros Inatos do Metabolismo Lipídico/diagnóstico , Erros Inatos do Metabolismo Lipídico/genética , Erros Inatos do Metabolismo Lipídico/patologia , Catarata/diagnóstico , 1-Acilglicerol-3-Fosfato O-Aciltransferase/genéticaRESUMO
Generalized pustular psoriasis (GPP) is a rare severe variant of psoriasis that is characterized by the abrupt widespread onset of small pustules accompanied by systemic manifestations of inflammation. It can arise in patients with a history of psoriasis as well as in those without, sometimes due to medication initiation or withdrawal, pregnancy, or infection. Generalized pustular psoriasis is thought to be driven primarily by innate immunity and unrestrained IL-36 cytokine activity. Recent genetic analyses have identified 3 genetic mutations that are associated with GPP-IL36RN, CARD14, and AP1S3-though these mutations only account for a minority of cases. There are many cutaneous pustular diseases that must be ruled out in the evaluation of a patient with suspected GPP, especially acute generalized exanthematous pustulosis (AGEP), and histologic analysis is the cornerstone of diagnosis. Although the quality of evidence to generate treatment recommendations for GPP is limited, management often includes utilization of systemic agents and/or biologics, usually with adjunctive topical treatment. Accumulating evidence suggests that biologic agents, especially infliximab, may be considered as first-line treatment of GPP, especially in severe acute cases, due to their abrupt onset of action and favorable side-effect profiles compared with oral systemic agents.
Assuntos
Produtos Biológicos , Psoríase , Dermatopatias Vesiculobolhosas , Doença Aguda , Produtos Biológicos/uso terapêutico , Proteínas Adaptadoras de Sinalização CARD/genética , Doença Crônica , Feminino , Guanilato Ciclase/uso terapêutico , Humanos , Infliximab/uso terapêutico , Interleucinas/genética , Interleucinas/uso terapêutico , Proteínas de Membrana/uso terapêutico , Gravidez , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Psoríase/genéticaRESUMO
BACKGROUND/OBJECTIVE: Herpes simplex virus (HSV) infection acquired in utero may present with non-vesicular dermatologic findings in affected newborns, which may pose a diagnostic dilemma. We aimed to describe and assess the range of non-vesiculobullous skin lesions that neonates with intrauterine HSV infection may manifest at birth. METHODS: We collected a multicenter case series and conducted a literature review of neonates with intrauterine HSV infection presenting with non-vesiculobullous cutaneous lesions. RESULTS: Twenty-two cases were reviewed, including six managed clinically by members of our team and 16 identified in the literature. Four (18%) were associated with twin pregnancies, and thirteen (59%) cases occurred in premature infants. Only four (18%) mothers had a documented history of HSV infection. Twelve (55%) cases resulted in poor outcomes, including long-term neurologic sequelae or death. Cutaneous manifestations included erosions, ulcerations, crusted papules or plaques, calcinosis cutis, excoriations, macules (erythematous, hypopigmented, or hyperpigmented), cutaneous atrophy, contractures, and bruising. About one-third of neonates developed new-onset vesicular lesions within a week of birth; in each of these cases, accurate diagnosis and therapy were delayed until appearance of vesicles. CONCLUSIONS: The range of dermatologic findings associated with intrauterine HSV is extremely broad, and the various morphologies present at birth likely reflect different stages of the ongoing evolution of an HSV infection that began in utero. Clinicians should have a low threshold for HSV testing in premature neonates born with atypical cutaneous lesions, since early detection and treatment of HSV may reduce morbidity and mortality from systemic complications.
Assuntos
Herpes Simples , Doenças do Recém-Nascido , Complicações Infecciosas na Gravidez , Anormalidades da Pele , Feminino , Herpes Simples/complicações , Herpes Simples/diagnóstico , Humanos , Recém-Nascido , Estudos Multicêntricos como Assunto , GravidezRESUMO
BACKGROUND/OBJECTIVE: Proteus syndrome, caused by a mosaic activating AKT1 variant, typically presents in toddlers with progressive, asymmetric overgrowth of the skin and bones. We aimed to define the spectrum of dermatologic disease in individuals with genetically confirmed Proteus syndrome. METHODS: We conducted a retrospective review of records from dermatologic examinations of individuals evaluated at the NIH with a molecular diagnosis of Proteus syndrome. The types, prevalence, and localization of dermatologic findings were assessed. RESULTS: Fifty-one individuals (29 males, 22 females, mean age: 9 years) with clinical features of Proteus syndrome had the mosaic c.49G>A, p.Glu17Lys AKT1 variant. Fifty (98%) had at least one cutaneous feature constituting current clinical diagnostic criteria, including vascular malformations in 42 (82%), epidermal nevus in 41 (80%), volar cerebriform connective tissue nevi in 34 (67%), and adipose dysregulation in 30 (59%). Forty-nine (96%) had at least one dermatologic finding not included within the diagnostic criteria, including confluent volar skin-colored to hypopigmented papules or nodules (n = 33, 65%), papules or nodules on the digits or face (n = 27, 53%), and nonlinear epidermal nevi (n = 15, 29%). Other frequently observed features include nail changes (n = 28, 55%), hyperpigmented macules (n = 27, 53%), patchy dermal hypoplasia (n = 18, 35%), gingival/oral mucosal overgrowth (n = 17, 33%), hypopigmented macules (n = 16, 31%), dental enamel changes (n = 9, 18%), acrochordons (n = 6, 12%), and lingual overgrowth (n = 4, 8%). CONCLUSIONS: The range of mucocutaneous features occurring in Proteus syndrome is broader than previously considered. These observations may assist in earlier diagnosis and management and provide novel insights regarding the pathogenesis of the condition.
Assuntos
Nevo , Síndrome de Proteu , Neoplasias Cutâneas , Malformações Vasculares , Criança , Feminino , Humanos , Masculino , Nevo/diagnóstico , Nevo/epidemiologia , Nevo/genética , Síndrome de Proteu/diagnóstico , Síndrome de Proteu/genética , Estudos Retrospectivos , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/genéticaRESUMO
AIMS: Fibrous cephalic plaques (FCPs) in individuals with tuberous sclerosis complex (TSC) may be excised for cosmetic reasons or biopsied to confirm lesion identification and TSC diagnosis. The aim of this study was to determine the range of histopathological features of FCPs. METHODS AND RESULTS: A retrospective analysis was conducted on 119 adults with TSC. Twenty-one lesions from 16 individuals were evaluated by a dermatopathologist. Additionally, we assessed whether lesion colour or histology varied by anatomical location. Seventy-six lesions were observed in 36 of 119 individuals. Erythematous lesions were more commonly found on the forehead, face or neck than on the scalp (odds ratio = 12.6, P = 0.0001). Thickened and disorganised collagen fibre bundles were present in 95% (20/21) of lesions. Perifollicular fibrosis was observed in 95% (20/21) of lesions, enhanced vascularity was observed in 52% (11/21) of lesions, and features of fibrofolliculoma were observed in 43% (9/21) of lesions. Other abnormalities included features similar to trichofolliculoma, follicular-derived, infundibular-type cysts, and abnormally arranged primitive hair follicles. CONCLUSIONS: FCPs in TSC show thickened bundles of collagen, and hamartomatous changes involving hair follicles. Recognition of these histopathological features may raise the possibility of unsuspected TSC or confirm FCP identification.
Assuntos
Dermatopatias/patologia , Esclerose Tuberosa/patologia , Adulto , Feminino , Fibrose/etiologia , Fibrose/patologia , Cabeça , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Dermatopatias/etiologia , Esclerose Tuberosa/complicaçõesRESUMO
Background: Erythrodermic psoriasis (EP) is a severe, rare form of psoriasis that can be life threatening. Treatment of EP is usually based on anecdotal evidence or past clinical experience, which is in part due to the rarity and often emergent nature of this psoriasis subtype.Methods: In December 2018, a keyword search for 'erythrodermic psoriasis' and 'treatment' was conducted. All studies investigating treatment strategies for EP in at least 2 patients were included in this review.Results: The database search yielded 921 results, and 23 studies comprising over 200 patients with EP were included in the final analysis. Biologics including tumor necrosis factor inhibitors (infliximab [n = 4], etanercept [n = 2], and adalimumab [n = 1]), interleukin-17 inhibitors (secukinumab [n = 3], ixekizumab [n = 2], and brodalumab [n = 1]), ustekinumab (n = 4), and guselkumab (n = 1) have been shown to rapidly achieve clinical improvement in patients with EP. The included studies also demonstrated efficacy of systemic agents cyclosporine (n = 4), etretinate (n = 3), and methotrexate (n = 1).Conclusions: A fair number of poor-quality studies support the use of various biologic and systemic therapies in the treatment of EP. Treatment of EP should be based on the severity of the clinical scenario as well as patient comorbidities.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Imunossupressores/uso terapêutico , Psoríase/tratamento farmacológico , Dermatite Esfoliativa/complicações , Humanos , Interleucina-17/antagonistas & inibidores , Interleucina-17/metabolismo , Psoríase/complicações , Resultado do Tratamento , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/metabolismoRESUMO
BACKGROUND: Proteus syndrome is an overgrowth disorder caused by a mosaic activating AKT1 variant. Hair abnormalities in Proteus syndrome have rarely been reported, and frequencies of such findings have not been elucidated. OBJECTIVE: To define the types and frequencies of hair findings in individuals with Proteus syndrome. METHODS: A cross-sectional study was conducted of individuals with clinical features of Proteus syndrome and a confirmed pathogenic variant in AKT1 evaluated between November 1996 and June 2019 at the National Institutes of Health Clinical Center. Medical records were reviewed for patterning, density, and color of hair on the body and scalp. RESULTS: Of 45 individuals evaluated, 29 (64%) had asymmetric hypertrichosis on the body. This included unilateral blaschkoid hypertrichotic patches overlying normal skin or epidermal nevi in 16 (36%), unilateral nonblaschkoid hypertrichotic patches in 11 (24%), and unilateral limb hypertrichosis in 10 (22%). Diffuse, scattered, or patchy changes in scalp hair density or color were present in 11 individuals (24%). LIMITATIONS: The retrospective, observational design, and limited longitudinal follow-up. CONCLUSIONS: Asymmetric variations in hair distribution, thickness, length, and color contribute to the overall mosaic appearance of the skin in Proteus syndrome, an observation that provides novel insights into the role of phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) signaling in skin appendage development.
Assuntos
Hipertricose/epidemiologia , Mosaicismo , Síndrome de Proteu/complicações , Proteínas Proto-Oncogênicas c-akt/genética , Adolescente , Adulto , Criança , Pré-Escolar , Estudos Transversais , Análise Mutacional de DNA , Feminino , Folículo Piloso/crescimento & desenvolvimento , Folículo Piloso/patologia , Humanos , Hipertricose/genética , Hipertricose/patologia , Masculino , Mutação , Fosfatidilinositol 3-Quinases/metabolismo , Prevalência , Síndrome de Proteu/diagnóstico , Síndrome de Proteu/genética , Proteínas Proto-Oncogênicas c-akt/metabolismo , Estudos Retrospectivos , Transdução de Sinais/genética , Adulto JovemAssuntos
Cor de Cabelo , Doenças do Cabelo/etiologia , Transtornos da Pigmentação/etiologia , Esclerose Tuberosa/complicações , Adulto , Idade de Início , Idoso , Diagnóstico Diferencial , Feminino , Doenças do Cabelo/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos da Pigmentação/diagnóstico , Estudos Retrospectivos , Adulto JovemRESUMO
Introduction: Many tumor necrosis factor (TNF)-alpha 'biosimilar' agents have been approved for the treatment of psoriasis and other autoinflammatory conditions. These biosimilars have the same structure as the originator biologic and have been shown to be equivalent in terms of safety and efficacy. However, given the method by which biosimilars are manufactured, they are not exact replicas of the originator, unlike generic forms of non-biologic medications. Therefore, there is controversy regarding whether these agents should be considered interchangeable with their originator biologics.Areas covered: The objective of this review is to summarize the safety data for each of the approved TNF-alpha biosimilars to determine whether or not these agents have appropriate safety profiles to replace their originator biologics.Expert opinion: Based on extrapolation of phase III investigations in patients with rheumatologic diseases, each of the approved anti-TNF agents have comparable efficacy, tolerability, and safety profiles to their originators. Studies in patients with psoriasis are more limited. Transitioning from a biologic to its biosimilar has also been shown to be similarly safe and immunogenetic compared to maintenance therapy with the originator. More post-marketing studies are needed to demonstrate the long-term safety in patients with psoriasis.
Assuntos
Produtos Biológicos/efeitos adversos , Medicamentos Biossimilares/efeitos adversos , Psoríase/tratamento farmacológico , Produtos Biológicos/administração & dosagem , Terapia Biológica/métodos , Medicamentos Biossimilares/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Fármacos Dermatológicos/efeitos adversos , Aprovação de Drogas , Substituição de Medicamentos , Humanos , Psoríase/patologia , Fator de Necrose Tumoral alfa/antagonistas & inibidoresRESUMO
Biologic drugs have revolutionized the treatment of psoriasis and other chronic inflammatory diseases. In recent years, many tumor necrosis factor-alpha 'biosimilar' agents have been developed. These biosimilars are similar in structure and function to their originator molecules, although they are not identical. Given that the safety and efficacy of the original biologic have already been proven, biosimilars are only required to show bioequivalence, or non-inferiority, to the reference biologic to be approved. Based on extrapolation of these non-inferiority data, biosimilars may be subsequently approved for all indications of the originator biologic, even without being directly studied in these various conditions. These biosimilar agents have been purported as a method to reduce the costs of biologic therapies, thereby increasing the accessibility of these medications and subsequently improving the treatment of psoriasis worldwide. The US Food and Drug Administration and/or the European Medicines Agency have approved biosimilars of adalimumab (Amjevita/Amgevita/Solymbic, Cyltezo, Imraldi/Hadlima, Hyrimoz/Hefiya/Halimatoz, Idacio, Hulio, Abrilada), etanercept (Erelzi, Benepali/Eticovo), and infliximab (Inflectra/Remsima, Renflexis/Flixabi, Ixifi/Zessly) for the treatment of psoriasis, and others are under review. There are many phase III data supporting the bioequivalence of these anti-tumor necrosis factor-alpha biosimilar agents in treating psoriasis and rheumatologic disease, which are discussed here. In general, these biosimilar agents have been shown to have equivalent efficacy, tolerability, and immunogenicity profiles compared to their originators in patients with rheumatologic disease, although studies in patients with psoriasis are fairly limited. Additional switching studies and post-marketing safety analyses are needed to assess the interchangeability of biosimilar agents with their reference products.
Assuntos
Produtos Biológicos/efeitos adversos , Medicamentos Biossimilares/efeitos adversos , Psoríase/tratamento farmacológico , Inibidores do Fator de Necrose Tumoral/efeitos adversos , Produtos Biológicos/administração & dosagem , Produtos Biológicos/farmacocinética , Medicamentos Biossimilares/administração & dosagem , Medicamentos Biossimilares/farmacocinética , Ensaios Clínicos Fase III como Assunto , Aprovação de Drogas , Substituição de Medicamentos/efeitos adversos , Substituição de Medicamentos/estatística & dados numéricos , Humanos , Vigilância de Produtos Comercializados/estatística & dados numéricos , Psoríase/imunologia , Equivalência Terapêutica , Resultado do Tratamento , Inibidores do Fator de Necrose Tumoral/administração & dosagem , Inibidores do Fator de Necrose Tumoral/farmacocinética , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/imunologiaRESUMO
In November 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released their recommendations regarding management of psoriasis in pediatric patients. The guidelines include information on quantification of disease severity, identification of triggers, assessment of comorbidities, and therapeutics specific to children with psoriasis. This review aims to highlight the most clinically significant considerations for dermatologists when managing pediatric psoriasis.
Assuntos
Psoríase , Criança , Comorbidade , Humanos , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Índice de Gravidade de Doença , Estados UnidosRESUMO
Pruritus, a very broad, subjective, and complex symptom, troubles the majority of patients with psoriasis. However, the subjective and multidimensional nature of the symptom renders it challenging for patients to appropriately communicate their experiences with itch to providers. This review explores current perspectives regarding the underlying mechanisms, assessment tools, burden, and treatment modalities for psoriatic pruritus. It emphasizes the significance of incorporating a standardized, thorough, and verified metric that incorporates severity, distribution, and character of pruritus as well as its effects on various aspects of quality of life. It also underscores the importance of continued research to fully understand the pathogenesis of psoriatic itch for establishment of novel, targeted therapeutics.
Assuntos
Prurido/etiologia , Psoríase/patologia , Betametasona/uso terapêutico , Calcitriol/análogos & derivados , Calcitriol/uso terapêutico , Efeitos Psicossociais da Doença , Fármacos Dermatológicos/uso terapêutico , Humanos , Prurido/psicologia , Prurido/terapia , Psoríase/complicações , Qualidade de Vida , Índice de Gravidade de DoençaRESUMO
YouTube is increasingly utilized by patients for health information. We aimed to assess the educational quality of YouTube videos about phototherapy and excimer laser for psoriasis. A cross-sectional analysis of YouTube videos was conducted using the search terms psoriasis phototherapy and psoriasis laser. Of the 200 videos screened, 124 met inclusion criteria. Sixty-eight (54.8%) were generated by device manufacturers advertising their product, 35 (28.2%) by healthcare professionals, and 8 (6.5%) by patients delivering testimonials from experiences receiving therapy. Fourteen (11.2%) contained high-quality patient education content, 28 (22.5%) were fair quality, and 82 (66.1%) were low quality. Compared to videos generated by advertisers, those created by healthcare providers were of higher educational quality and more likely to be patient-directed. Neither the number of views nor interaction differed significantly among videos of varying educational quality, between videos presenting evidence-based versus non-evidence-based claims about psoriasis, and between videos conveying positive versus negative messages regarding medical consultation. Overall, the majority of YouTube videos about phototherapy and excimer laser advertise devices are of fair-to-low educational quality and are not patient-centric. The addition of more videos that accurately and holistically discuss patient-relevant aspects of these therapies may transform YouTube into a more effective resource for informing patient choices.
Assuntos
Informação de Saúde ao Consumidor , Lasers de Excimer/uso terapêutico , Educação de Pacientes como Assunto , Fototerapia , Psoríase/terapia , Mídias Sociais , Gravação em Vídeo , Estudos Transversais , HumanosRESUMO
Background: Inverse psoriasis often requires a targeted treatment strategy due to the inherent sensitivity, thinness, and occlusion of flexural areas. However, most treatment recommendations are based on anecdotal evidence.Methods: A systematic literature search was conducted in October 2018 in Pubmed, Scopus, Embase, and Cochrane Library with keywords 'inverse psoriasis,' 'genital psoriasis,' and 'treatment.' All prospective studies assessing efficacy of treatments for inverse psoriasis that had a sample size of at least 10 patients were included in our analysis.Results: The initial search yielded 340 results, and 14 studies were included in the final analysis. These studies comprised over 1000 patients with mild to severe psoriasis involving axillary, inframammary, facial, and/or anogenital regions. The included studies demonstrated efficacy of topical immunomodulators (N = 7), vitamin D analogs (N = 4), topical corticosteroids (N = 3), antiseptics (N = 2), and biologics (N = 1) in improving genital and flexural psoriasis symptoms.Conclusions: There is a paucity of high-quality studies on which to base treatment recommendations, especially with regard to the role of systemic and biologic therapies. Few studies, many of which are of low evidence quality, suggest that topical immunomodulators, vitamin D analogs, and mid-to-high-potency topical corticosteroids may be effective treatments, but more randomized controlled trials are needed.
Assuntos
Corticosteroides/administração & dosagem , Fatores Imunológicos/administração & dosagem , Psoríase/tratamento farmacológico , Vitamina D/análogos & derivados , Administração Tópica , Anti-Infecciosos Locais/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Humanos , Estudos Prospectivos , Resultado do Tratamento , Vitamina D/uso terapêuticoRESUMO
YouTube is becoming an increasingly popular resource for patients seeking knowledge regarding treatment options for dermatologic conditions. This study assessed the quality of content on YouTube regarding topical treatment for psoriasis. A cross-sectional analysis of YouTube videos was conducted using search terms related to psoriasis topical therapies. Of the 400 videos screened, 199 met inclusion criteria. One hundred and ten (55.3%) videos discussed natural treatments, 56 (28.1%) discussed therapies with grade A recommendations by the American Academy of Dermatology, 22 (8.5%) discussed therapies with grade B recommendations, and 14 (7.0%) discussed combinations of these. One hundred twelve (56.3%) were financially biased, 36 (18.1%) were uploaded by natural remedy channels without evident financial interests, 31 (15.5%) were patient-generated testimonials, and 20 (10.1%) featured healthcare professionals. Patient testimonials had the most views and user interaction while videos depicting healthcare professionals had the lowest. Videos criticizing medically-prescribed therapies and consultations with healthcare providers had significantly more views than those encouraging seeking medical expertise. Overall, YouTube videos about topical treatment options for psoriasis largely favor natural treatments over medical recommendations and discourage seeking medical advice. Dermatologists should consider posting information to YouTube to increase the volume of evidence-based, patient-directed material available through this platform.